Eli Lilly And Company

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This study tests whether tirzepatide, a once-weekly injection, helps teenagers with obesity or overweight (with related health issues) lose weight. About 160 teens will receive either tirzepatide or a placebo for 72 weeks, alongside lifestyle advice. The main goal is to see if bo…

This phase 2 trial tests whether mazdutide, a drug given as a shot, can help people with alcohol use disorder drink less. About 308 participants will receive either mazdutide or a placebo for up to 36 weeks. The study measures changes in drinking behaviors using a standard questi…

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…

This study tests a drug called lebrikizumab against a placebo in 221 adults and teenagers with moderate-to-severe hand and foot eczema. The treatment is given as an injection under the skin over 16 weeks. The main goal is to see if the drug can clear or nearly clear the skin rash…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This large Phase 3 study tests an injectable drug called lepodisiran in about 17,300 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either already have heart disease or are at high risk for a first heart event. The goal…

This study tests different dosing schedules of the drug donanemab in about 1,175 people with early symptomatic Alzheimer's disease. The goal is to find a regimen that lowers brain amyloid plaques while reducing the risk of a side effect called ARIA-E (brain swelling or small blee…

This phase 3 trial is testing whether the drug retatrutide can lower the chance of serious heart problems (like heart attacks and strokes) and slow kidney disease in 10,000 overweight adults who already have heart or kidney disease. Participants receive either retatrutide or a pl…

This early-stage study tests an investigational drug called LY4086940 in healthy people and those with overweight, obesity, or type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 participants will receive single or multiple doses …

This phase 3 trial is testing different ways to increase the dose of retatrutide, a new weight-loss drug, in 600 people with obesity or overweight who do not have type 2 diabetes. The study lasts about 113 weeks and measures weight loss, waist size, and other health markers. The …

This phase 3 study tests whether donanemab, an antibody given through an IV, can safely slow cognitive decline in 1500 people with early Alzheimer's. Participants receive either the drug or a placebo for up to 93 weeks. The main goal is to measure changes in thinking and daily fu…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This Phase 3 trial tests a daily pill called orforglipron in 487 adults with high blood pressure who are also overweight or obese. The study measures how well the drug lowers blood pressure and body weight compared to a placebo. It is currently active but not recruiting.

This Phase 3 trial is testing a once-daily pill called orforglipron in nearly 1,000 people with high blood pressure who are also overweight or have obesity. The study compares the drug to a placebo to see if it safely lowers blood pressure. Participants may be untreated or on sta…

This Phase 3 study tests an experimental once-daily pill called orforglipron in about 487 adults who have both high blood pressure and obesity or overweight. The main goal is to see if the drug lowers blood pressure more than a placebo. Researchers will also check for changes in …

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This phase 2 study tests two drugs, bimagrumab and tirzepatide, alone or together, to see if they help adults with obesity or overweight lose weight safely. About 252 participants without type 2 diabetes will take the drugs or a placebo for up to 70 weeks. The main goal is to mea…

This Phase 3 study tests a weekly injection called retatrutide in about 1,946 people with severe obesity (BMI ≥35) and established heart disease. The goal is to see if it helps with weight loss and improves heart-related health measures over 113 weeks compared to a placebo. Parti…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This phase 2 trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (temozolomide) helps children and young adults with newly diagnosed high-grade glioma live longer without their cancer growing. About 45 participants will receive either the combination…

This phase 3 trial tests tirzepatide, a once-weekly injection, in 905 adults with type 1 diabetes who are also overweight or obese. Participants will receive either tirzepatide or a placebo for about 49 weeks. The study measures changes in blood sugar control (HbA1c) and body wei…

This Phase 2 trial tests whether tirzepatide, a drug already used for diabetes and weight loss, can improve kidney health in 140 people with obesity and chronic kidney disease (with or without type 2 diabetes). Researchers will use MRI scans to measure changes in kidney fat and b…

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…

This Phase 3 trial tests a daily pill called orforglipron to see if it helps people with obesity or overweight lose weight. About 600 participants will take either the drug or a placebo for around 18 months. The study focuses on weight reduction and related health measures like w…

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…

This Phase 3 trial is testing a once-daily pill called orforglipron to see if it helps people with obesity or overweight lose weight, both in those with and without type 2 diabetes. About 1,200 participants will take either the drug or a placebo for a set period. The goal is to f…

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This study tests whether baricitinib, an oral drug, is safe and effective for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. Participants had not responded well to standard treatments. The main goal is to reduce e…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, along with standard topical steroids. The…

This early-stage trial tests an experimental drug called LY3295668 erbumine in children whose neuroblastoma has returned or not responded to treatment. The study aims to find a safe dose and see if the drug can shrink tumors, either alone or with standard chemotherapy. About 71 p…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue treatment. The goal is to see if the drug can keep…

This Phase 3 trial is testing a once-daily pill called orforglipron in 600 adults who are overweight or have obesity and also have type 2 diabetes. The study compares the drug to a placebo to see if it helps lower blood sugar and body weight over about 18 months. Participants mus…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This study tests a once-weekly injection called retatrutide to help people with obesity or overweight lose weight. About 250 participants without type 2 diabetes will receive either the drug or a placebo for 65 weeks. The main goal is to see how much weight they lose and if it is…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or …

This study tests whether adding the drug abemaciclib to standard chemotherapy can help people with Ewing's sarcoma whose cancer has returned or not responded to treatment. About 46 children and young adults will take part. The goal is to see if the combination slows tumor growth …

This phase 3 trial tests whether retatrutide is better than tirzepatide for weight loss in 800 adults with obesity. Participants receive one of the two drugs for about 89 weeks. The study measures changes in body weight, BMI, waist size, and other health markers.

This study tests a new weekly medicine, retatrutide, against an existing one, semaglutide, in about 1250 adults with type 2 diabetes whose blood sugar is not well controlled by metformin. The goal is to see which works better at lowering blood sugar and weight over 26 months. Par…

This Phase 3 trial tests retatrutide, a once-weekly injection, in 1000 adults with type 2 diabetes who are overweight or obese. The study also looks at a subset of participants with obstructive sleep apnea. Over 89 weeks, researchers will measure weight loss, changes in sleep apn…

This Phase 2 trial tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis. The goal is to see if the drug can slow the appearance of new brain lesions seen on MRI scans. The study lasts about 9 months, with an additional 6 mon…

This phase 3 trial tests a new oral hormone therapy called imlunestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 8,000 people with ER+/HER2- early breast cancer who have already had 2-5 years of hormone therapy and are at higher risk of recur…

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…

This phase 2 trial tests different doses of tirzepatide in 414 adults with type 2 diabetes and obesity who already take metformin. The goal is to see if the drug helps with weight loss and blood sugar control. Participants receive either tirzepatide or a placebo for about 89 week…

This study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…

This study tests whether the drug selpercatinib can delay the return of lung cancer in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants have already had surgery or radiation to remove or treat their cancer. They will…

This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…

This study tests an investigational drug called retatrutide in 643 adults with obesity. The goal is to see if it helps maintain weight loss over about 2.5 years. Participants first take the drug for 80 weeks, then are randomly assigned to continue the drug or switch to a placebo …

This study tests whether galcanezumab, a monthly injection, can prevent chronic migraine in 312 adolescents aged 12 to 17. Participants receive either the drug or a placebo for 3 months. The main goal is to see if the drug reduces the number of migraine days per month.

This phase 3 trial tests tirzepatide, a once-weekly injection, in 465 adults with type 1 diabetes who are also overweight or obese. Participants receive either tirzepatide or a placebo for about 20 months. The study measures changes in blood sugar control (HbA1c) and body weight …

This phase 3 study tests whether the targeted drug abemaciclib can help people with stage IV lung cancer that has a KRAS mutation and has worsened after chemotherapy. About 450 participants received either abemaciclib or another targeted drug (erlotinib), both alongside best supp…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …

This program monitors 4000 people with schizophrenia who receive Zyprexa Relprevv, a long-acting injection. The goal is to track and reduce the risk of a rare but serious reaction called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS happ…

This early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the…

This study tests whether galcanezumab, a monthly injection, can prevent migraines in children and teens aged 6 to 17 with episodic migraine. Over 500 participants received either the drug or a placebo for 3 months. The goal is to see if the drug reduces the number of migraine day…

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…

This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and how the body handles the drug. Researchers will also measure weight changes and blood sugar levels. The study involves about 300 people and …

This study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…

This Phase 3 trial tests whether adding ramucirumab (a drug that blocks blood vessel growth) to the standard targeted therapy erlotinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) live longer without their cancer getting worse. About 545 peop…

This phase 3 trial tests whether tirzepatide, a drug already used for diabetes and weight loss, can reduce the risk of heart attacks, strokes, heart failure, and death in over 15,000 adults with obesity. Participants either have established heart disease or are at high risk. The …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study tests a once-weekly injection called retatrutide in 320 adults with type 2 diabetes and moderate to severe kidney disease who are not controlling their blood sugar well on insulin. Participants will receive either the drug or a placebo for about 14 months. The goal is …

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This study looks at how well and how safely the drug mirikizumab works over the long term for people with Crohn's disease. About 996 adults who were in earlier mirikizumab studies will continue treatment. The goal is to see if the drug can keep the gut healed and symptoms under c…

This study compares the long-term effects of tirzepatide, a newer diabetes medication, with standard treatments in 780 adults who were diagnosed with type 2 diabetes within the last 4 years. Participants must be on metformin alone and have moderately high blood sugar levels. The …

This Phase 3 study tests an injected drug called remternetug against a placebo in 1,400 people with early Alzheimer's who are at risk for worsening memory and thinking. The goal is to see if the drug can delay or prevent meaningful decline in daily function. Participants may be i…

This study tests a new daily pill, orforglipron, to help adults with obesity or overweight who also have weight-related conditions like high blood pressure or sleep apnea lose weight. About 3,100 participants will take either the pill or a placebo for 72 weeks, with some continui…

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, receiving either the combination or f…

This study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…

This study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and inflammation. Participants receive either the drug or a placebo for about 62 weeks. The goal is to find a safe and ef…

This phase 3 trial tests a drug called lebrikizumab, given as a shot, for people with moderate-to-severe eczema that hasn't improved with standard creams. Some participants also use a steroid cream. The study involves 301 adults and lasts about 62 weeks. Researchers are checking …

This study was designed to test whether volenrelaxin could help adults with chronic kidney disease by reducing protein in the urine and preserving kidney function. It was a phase 2, placebo-controlled trial planned to last about 24 weeks. However, the study was withdrawn before e…

This phase 3 trial tests whether a once-daily pill called orforglipron can improve sleep apnea in 600 adults with moderate-to-severe sleep apnea who are also obese or overweight. Participants are split into two groups: those who cannot or will not use a CPAP machine, and those wh…

This study aimed to test two drugs, bimagrumab and tirzepatide, alone or together, for helping adults with obesity or overweight and type 2 diabetes lose weight. It was planned for about 13 months but was withdrawn before enrolling any participants. The main goal was to see how m…

This study tests two drugs, LY3841136 and tirzepatide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 350 participants will take the drugs or a placebo for up to 64 weeks. The goal is to see if these treatments are safe and eff…

This early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can sh…

This study tests whether donanemab, a monthly infusion, can delay or prevent memory and thinking problems in people who have early signs of Alzheimer's disease but no symptoms yet. About 3000 participants with a positive blood test for Alzheimer's-related proteins are being follo…

This study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…

This early-stage study tests a new drug called LY3549492 in 120 healthy adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it over about 8 weeks. Participants receive multiple doses of the drug, and researchers monito…

This study tests a new drug called LY3848575 for people with long-term nerve pain starting in the feet and moving up the legs. About 558 participants will receive either the drug or a placebo to see if it safely reduces pain. The trial lasts up to 30 weeks and measures pain inten…

This early-stage study is testing a single dose of remternetug in 24 healthy Chinese adults to see if it is safe and how the body processes it. Participants will have blood tests and be monitored for side effects over about 25 weeks. The study does not aim to treat any disease, b…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…

This study looks at how long you need to fast and how stopping the diabetes/weight-loss drug tirzepatide changes the amount of food left in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 people with type 2 diabetes or obesity. The goal …

This study tests a new drug called LY3981314 in healthy people to see if it is safe and how the body handles it. About 76 participants will receive a single injection under the skin and be monitored for up to 25 weeks. The goal is to gather safety information, not to treat any di…

This study looks at how fasting and temporarily stopping the diabetes drug dulaglutide affect how much food and liquid stays in the stomach after a meal. About 20 people with type 2 diabetes will have their stomachs checked with ultrasound after eating. The goal is to understand …

This study looks at how well three different tablet versions of the drug LY4100511 are absorbed by the body in 48 healthy adults. It also checks if taking a common stomach acid medicine (a proton pump inhibitor) changes absorption. The goal is to find the best tablet form for fut…

This study looks at how a new drug called LY3537031 gets into the blood and how the body clears it. It involves 46 healthy volunteers who receive the drug either under the skin in different spots or into a vein. The goal is to understand the best way to give the drug and check it…

This study follows 1,400 people with early-stage Alzheimer's or mild cognitive impairment to understand how the disease affects healthcare costs and daily life over time. Participants are not given any experimental treatment. The goal is to gather information for research purpose…